Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Israel strikes Iranian nuclear development facilities, Tehran vows retaliation - 2Katz, IDF: We assassinated IRGC intelligence chief Majid Khademi
- 3Sean 'Diddy' Combs faces new sexual assault allegations, currently under investigation by Los Angeles Sheriff's Department
- 4What to know about voluntary chocolate recall
- 5Experience Sports in Dubai: A Daredevil's Aide
- Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests
- Artemis moon mission breaks record for distance from Earth
- The powerful new Rubin Observatory just found 11,000 new asteroids and measured 'tens of thousands more'
- Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- 6 Modest and Strong Tire Brands
- Massive supernova explosion may have created a binary black hole
- How the Iran war may affect your money and bills
- Spain’s Picos de Europa: What to see and do in ‘the world’s most beautiful place’
- France will build a new aircraft carrier as it increases defense spending
